DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$10.02M, compared with -$7.69M a year earlier. Trailing-twelve-month EBITDA was -$35.03M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -34.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.02M-15.0% QoQ
- Last fiscal yearDec 2025
- -$32.7M-34.1% YoY
- LTMMar 2026
- -$35.03M-30.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -30.4% | +100.0% | +130.4 pp |
| 1 year | -34.1% | +100.0% | +134.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (32.7M) USD
- Year-over-year change
- -34.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (32.7M) | -34.1% |
| FY2024 | 2024-12-31 | (24.38M) | -26.2% |
| FY2023 | 2023-12-31 | (19.31M) | -41.7% |
| FY2022 | 2022-12-31 | (13.62M) | -0.6% |
| FY2021 | 2021-12-31 | (13.54M) | — |
EBITDA vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's LTM Mar 2026 EBITDA of -$35.03M is the 2nd highest of the 7 companies compared; the peer median is -$104.36M.
- Its year-over-year change of -30.1% is the 4th highest of 7, against a peer median of -96.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$5.76M | -220.1% | +92.3% | 2.5% | |
| LTM Mar 2026 | -$35.03M | -30.1% | — | — | |
| LTM Mar 2026 | -$39.25M | -164.0% | — | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.21M | -28.4% | — | 864.8% |
| LTM Mar 2026 | -$119.51M | -312.9% | — | 597.6% | |
| LTM Mar 2026 | -$150.42M | +6.1% | — | 16919.8% | |
| LTM Jun 2026 | -$498.21M | -6.5% | — | 13823.7% | |
| Peer median (excluding DMAC) | -$104.36M | -96.2% | +92.3% | 864.8% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.77M | 7.84M | 13.11M | 19.06M | 24.61M |
| Selling, General & Admin | 4.88M | 6.16M | 8.16M | 7.62M | 9.78M |
| Operating Expenses | 13.65M | 14M | 21.27M | 26.68M | 34.4M |
| Depreciation & Amortization | 24K | 25K | 30K | 39K | 43K |
| EBITDA | (13.54M) | (13.62M) | (19.31M) | (24.38M) | (32.7M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (13.65M) | (14M) | (21.27M) | (26.68M) | (34.4M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 2.3M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 82K | 353K | 1.93M | 2.27M | 1.66M |
| Income Before Tax | (13.56M) | (13.65M) | (19.34M) | (24.41M) | (32.74M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 28K | 28K | 43K | 30K | 28K |
| Net Income | (13.59M) | (13.68M) | (19.38M) | (24.44M) | (32.77M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.65) | (0.52) | (0.60) | (0.60) | (0.70) |
| EPS (Diluted) | (0.65) | (0.52) | (0.60) | (0.60) | (0.70) |
| Weighted Avg Shares | 20.77M | 26.44M | 32.57M | 40.4M | 46.98M |
| Weighted Avg Shares (Diluted) | 20.77M | 26.44M | 32.57M | 40.4M | 46.98M |
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.